Salvador P. P.
- Country
- Spain
- Department
- N/A
Research Overview
- Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Safety of Vamifeport in Adults with HFE-Related Hereditary Hemochromatosis
- Evaluation of Etavopivat, a Pyruvate Kinase Activator, in a Randomized, Placebo-Controlled Study for Sickle Cell Disease in Patients Aged 12 to 65 Years
- Efficacy and Safety Evaluation of Mitapivat in Transfusion-Dependent Alpha- or Beta-Thalassemia: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 43 of 107 partner sites.
Specializations
Hematological Disorders
The investigator specializes in treating blood disorders, with particular focus on sickle cell disease and its complications. Their research encompasses innovative therapeutic approaches for managing vaso-occlusive episodes in SCD patients.
- Acute VOC Management
- Hemoglobin Improvement Strategies
- Crisis Prevention Protocols
Their work extends to evaluating novel therapeutic agents for preventing and treating SCD-related complications.
Thalassemia Research
The investigator focuses on both transfusion-dependent and non-transfusion-dependent thalassemia, investigating therapeutic solutions for alpha and beta variants of the condition.
- Anemia Management
- Transfusion Burden Reduction
- Novel Treatment Approaches
Their research aims to advance treatment options for patients with various forms of thalassemia.
Therapeutic Innovation
The investigator studies multiple innovative compounds including mitapivat, etavopivat, and crovalimab for treating hereditary blood disorders.
- Drug Safety Assessment
- Clinical Efficacy Evaluation
- Patient Response Monitoring
Their work encompasses comprehensive evaluation of new therapeutic agents for blood disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.